Manoj Mohan, DO
Allergy & Immunology · Okemos, MINPI 1821295213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 516 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 25.2% of the total.
Across 516 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Sanofi$958
- Genentech USA, Inc.$532
- Optinose US, Inc.$514
- Regeneron Healthcare Solutions, Inc.$453
- plus $4K from 27 others
What the payments were for
- Food & beverage$9,82598%
- Education$1752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 129 | $2,520 |
| GSK | 87 | $1,510 |
| Sanofi | 42 | $958 |
| Genentech USA, Inc. | 27 | $532 |
| Optinose US, Inc. | 26 | $514 |
| Regeneron Healthcare Solutions, Inc. | 17 | $453 |
| Pfizer | 21 | $335 |
| Novartis | 15 | $313 |
| CSL Behring | 13 | $286 |
| Alk-abello, Inc | 14 | $264 |
| Teva Pharmaceuticals USA, Inc. | 16 | $232 |
| Pharming Healthcare, Inc. | 12 | $222 |
| Grifols USA, LLC | 12 | $218 |
| Kaleo, Inc. | 12 | $194 |
| Boehringer Ingelheim | 10 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $174 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $161 |
| AbbVie | 3 | $158 |
| Amgen | 8 | $134 |
| Organon | 7 | $112 |
| Shire North American Group Inc | 5 | $90 |
| Biocryst US Sales Co., LLC | 3 | $84 |
| Covis Pharma GmbH | 5 | $72 |
| Phadia US Inc. | 4 | $69 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Lilly USA, LLC | 2 | $31 |
| Octapharma USA, Inc. | 2 | $30 |
| Biocryst Pharmaceuticals, Inc. | 1 | $21 |
| Circassia Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$119
- Xhance$113
- FASENRA$108
- TRELEGY ELLIPTA$100
How this compares
$10,000 in reported general payments places this provider in the 75th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 12 | $270,940 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 126 | $160,692 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $47,587 |
| NucalaMepolizumab | 12 | $43,807 |
| XolairOmalizumab | 11 | $32,174 |
| Arnuity ElliptaFluticasone Furoate | 57 | $20,539 |
| Spiriva RespimatTiotropium Bromide | 19 | $20,263 |
| Qvar RedihalerBeclomethasone Dipropionate | 24 | $17,153 |
| Epinephrine | 53 | $16,391 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $15,026 |
| Fluticasone Propionate HfaFluticasone Propionate | 18 | $13,891 |
| Pulmicort FlexhalerBudesonide | 25 | $12,035 |
| XhanceFluticasone Propionate | 19 | $11,848 |
| RyaltrisOlopatadine Hcl/Mometasone | 30 | $11,390 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $9,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $1,510 | $272,625255 claims |
| CSL BehringHaegarda | $286 | $270,94012 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $32 | $27,78183 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $2,520 | $27,06159 claims |
| Boehringer IngelheimSpiriva Respimat | $182 | $20,26319 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $232 | $17,15324 claims |
| Optinose US, Inc.Xhance | $514 | $11,84819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Okemos
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
- Jason ParisLivonia$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.